The number of patents that is increasing in the field of radiopharmacy
from 2000 until 2013 are over 4500 patents that have been deposited nationaly and
internationally. However, only few of these patents had reached the market and
became true radiopharmaceuticals. This paradigm is changing and the development
of nanomaterials may be one of these factors. The development of nano-drugs for
cancer imaging and therapy is desired. Besides all the investment (over 50 billion
dollars) around the world, the result is quite promising and reveals a great deal of
application of nanotechnology. In this review, some aspects related to tumor
environment and radiopharmaceuticals (DDS) are studied.
Keywords: Cancer, imaging, monoclonal antibodies, nanotechnology, nuclear
medicine, oncology, peptides, radiopharmacy.
Rights & PermissionsPrintExport